Table 3.
Preclinical studies based on the use of TALEN and ZFN technologies to provide more effective and universal CAR-T cell
| Condition | CAR | Target locus (knocked out) | Study model | Ref |
|---|---|---|---|---|
| TALEN | ||||
| MM | BCMA | CD20 |
MM.1S cell line NSG mice |
[129] |
| B-ALL | CD19 |
TRAC CD52 |
NSG mice | [130, 131] |
| BL | CD22 |
TRAC CD25 PD-1 |
RAJI cell line NSG mice |
[132] |
| T-ALL | CD3 | TRAC |
Jurkat cell line NSG mice |
[133] |
| B-ALL | CD20 |
TRAC PD-1 |
Cell line | [134] |
| BL | CD22 | GM-CSF | RAJI and Daudi cell line | [135] |
| B-ALL | CD19 |
TRAC CD52 |
NALM6 cell line NSG mice |
[136] |
| ZFN | ||||
|
B-ALL CLL MCL |
CD19 | TRAC | Primary tumor cells | [126] |
| B-ALL | CD19 | TRAC | Cell line | [7] |
Note: ALL acute lymphoblastic leukemia, BCMA B cell maturation antigen, TRAC T cell receptor alpha constant, PDCD1 or PD1 programmed cell death protein 1, GM-CSF granulocyte-macrophage colony-stimulating factor, MM multiple myeloma, MCL mantle cell lymphoma, BL Burkitt’s lymphoma